Abstract
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an enzyme defect with an X-linked recessive inheritance pattern that predisposes to hemolysis in response to certain triggers such as medications, infections, or diet (fava beans). The most important aspect in management of G6PD deficiency in both pregnant and nonpregnant patients is avoidance of triggers. Medications to avoid include antimalarials (dapsone, primaquine), antimycobacterials, antineoplastic agents, methylene blue, and antibiotics such as nitrofurantoin. Common anesthetic agents such as sevoflurane, ketamine, fentanyl, and benzodiazepines have not been reported to cause a hemolytic crisis in G6PD-deficient patients. Most pregnant women with G6PD deficiency can have neuraxial analgesia, and opioids and bupivacaine are safe to use.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Cappellini M, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371(9606):64–74.
Manganelli G, Masullo U, Passarelli S, Filosa S. Glucose-6-phosphate dehydrogenase deficiency: disadvantages and possible benefits. Cardiovasc Hematol Disord Targets. 2013;13(1):73–82.
Luzzatto L, Nannelli C, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. Hematol Oncol Clin North Am. 2016;30(2):373–93.
Luzzatto L, Seneca E. G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. Br J Haematol. 2014;164(4):469–80.
Monteiro WM, Franca GP, Melo GC, Queiroz AL, Brito M, Peixoto HM, et al. Clinical complications of G6PD deficiency in Latin American and Caribbean populations: systematic review and implications for malaria elimination programmes. Malar J. 2014;13(1):70.
Hecker PA, Leopold JA, Gupte SA, Recchia FA, Stanley WC. Impact of glucose-6-phosphate dehydrogenase deficiency on the pathophysiology of cardiovascular disease. Am J Physiol Heart Circ Physiol. 2013;304(4):H491–500.
Ho H-Y, Cheng M-L, Chiu DT-Y. Glucose-6-phosphate dehydrogenase—beyond the realm of red cell biology. Free Radic Res. 2014;48(9):1028–48.
Francis RO, Jhang JS, Pham HP, Hod EA, Zimring JC, Spitalnik SL. Glucose-6-phosphate dehydrogenase deficiency in transfusion medicine: the unknown risks. Vox Sang. 2013;105(4):271–82.
Spencer NY, Stanton RC. Glucose 6-phosphate dehydrogenase and the kidney. Curr Opin Nephrol Hypertens. 2017;26(1):43–9.
Yoshida A, Beutler E, Motulsky AG. Human glucose-6-phosphate dehydrogenase variants. Bull World Health Organ. 1971;45(2):243–53.
Mockenhaupt FP, Mandelkow J, Till H, Ehrhardt S, Eggelte TA, Bienzle U. Reduced prevalence of Plasmodium falciparum infection and of concomitant anaemia in pregnant women with heterozygous G6PD deficiency. Trop Med Int Health. 2003;8(2):118–24.
van de Mheen L, Smits SM, Terpstra WE, Leyte A, Bekedam DJ, van den Akker ESA. Haemolytic anaemia after nitrofurantoin treatment in a pregnant woman with G6PD deficiency. BMJ Case Rep. 2014;2014:pii: bcr2013010087.
Abdulhadi NH. Glucose 6 phosphate dehydrogenase (G6PD) deficiency is a possible risk factor for the development of preeclampsia. Med Hypotheses. 2004;62(5):780–2.
Afzal-Ahmed I, Mann GE, Shennan AH, Poston L, Naftalin RJ. Preeclampsia inactivates glucose-6-phosphate dehydrogenase and impairs the redox status of erythrocytes and fetal endothelial cells. Free Radic Biol Med. 2007;42(12):1781–90.
Perkins RP. The significance of glucose-6-phosphate dehydrogenase deficiency in pregnancy. Am J Obstet Gynecol. 1976;125(2):215–23.
Sirugo G, Schaefer EA, Mendy A, Sabeti P, West B, Bailey R, et al. Is G6PD A- deficiency associated with recurrent stillbirths in The Gambia? Am J Med Genet. 2004;128A(1):104–5.
Cramer DW, Wise LA. The epidemiology of recurrent pregnancy loss. Semin Reprod Med. 2000;18(4):331–40.
Keller CC, Joosten M, Middeldorp AM, Knapen MFCM. Fetal anemia caused by the Guadalajara variant of G6PD deficiency. Prenat Diagn. 2015;35(12):1255–7.
Bubp J, Jen M, Matuszewski K. Caring for glucose-6-phosphate dehydrogenase (G6PD)-deficient patients: implications for pharmacy. P T. 2015;40(9):572–4.
Altikat S, Ciftçi M, Büyükokuroğlu ME. In vitro effects of some anesthetic drugs on enzymatic activity of human red blood cell glucose 6-phosphate dehydrogenase. Pol J Pharmacol. 2002;54(1):67–71.
Cho YS, Chung BY, Park CW, Kim HO. Seizures and methemoglobinemia after topical application of eutectic mixture of lidocaine and prilocaine on a 3.5-year-old child with molluscum contagiosum and atopic dermatitis. Pediatr Dermatol. 2016;33(5):e284–5.
Guay J. Methemoglobinemia related to local anesthetics: a summary of 242 episodes. Anesth Analg. 2009;108(3):837–45.
Barash M, Reich K, Rademaker D. Lidocaine-induced methemoglobinemia: a clinical reminder. J Am Osteopath Assoc. 2015;115(2):1146–98.
Elyassi AR, Rowshan HH. Perioperative management of the glucose-6-phosphate dehydrogenase deficient patient: a review of literature. Anesth Prog. 2009;56(3):86–91.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Chen, J., Mankowitz, S.K.W. (2018). Glucose 6 Phosphate Deficiency. In: Mankowitz, S. (eds) Consults in Obstetric Anesthesiology. Springer, Cham. https://doi.org/10.1007/978-3-319-59680-8_66
Download citation
DOI: https://doi.org/10.1007/978-3-319-59680-8_66
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-59679-2
Online ISBN: 978-3-319-59680-8
eBook Packages: MedicineMedicine (R0)